Insights & Intelligence for Regulatory Leaders

If you are reading this from inside a large MedTech organization, you may be thinking: we have ten times the engineering staff. Why can’t we just build this ourselves?

We-Should-Just-Build-This-Ourse…

It is a fair question.

But software has a well-known paradox. Adding more people to a complex project does not make it go faster. It usually makes it go slower. More coordination. More handoffs. More meetings about meetings. More surface area for misalignment

A large IT organization is optimized for breadth — supporting dozens of systems, managing infrastructure, keeping the lights on across the enterprise

That is valuable work.

But it is fundamentally different from building and sustaining a deep vertical product over a decade.

The people on your team have day jobs. They run devices through regulatory pathways, manage quality systems, support manufacturing, and commercialize products globally

Building a regulated platform is not a side quest.

It is a second company

What the Numbers Actually Look Like

When people compare license fees to internal builds, they stop at the wrong baseline

The real comparison is:

Licensing a specialized platform
versus
Standing up and operating a regulated software company inside your enterprise

Product management.
UX research.
Engineering.
Regulatory SMEs.
Validation and QA.
Security operations.
Compliance programs.
24/7 support.
Infrastructure.
Multi-year modernization

AI makes some of that faster.

It does not make any of it optional

With a specialized vendor, that investment is amortized across an entire customer base.

With an internal build, the full long tail of ownership falls on you

And most of that spend ends up recreating the 80 percent that has already been solved — all because someone decided the remaining 20 percent justified building from scratch

The return on that 20 percent rarely survives honest scrutiny.

‍

The Questions That Should Keep You Honest

It is easy to get excited about how fast something can be built.

The harder exercise is asking what happens in year three, year five, year eight

When your VP of Regulatory Affairs leaves, who maintains validation documentation?

When regulations change across jurisdictions simultaneously, who redesigns workflows and pushes a validated release before the deadline?

When an auditor asks for change control history and disaster recovery test results, who is accountable?

Internal initiatives often stumble not because engineers cannot prototype, but because sustaining them for a decade is brutally hard

Sponsors move on. Budgets change. Teams reorganize.

Regulatory systems do not get to pause.

They must remain inspection-ready through acquisitions, divestitures, and leadership turnover

Systems of record are commitments, not experiments

AI Changed the Tools, Not the Gravity

I am genuinely excited about what AI enables. It will reshape regulatory operations, reduce headcount growth, compress timelines, and raise expectations for every vendor in this space

What it has not done is repeal gravity.

Most of what AI replaces today is busy work. That is enormously valuable. But busy work was never the strategic bottleneck

The hard parts remain.

• Deciding submission strategy.
• Interpreting regulator feedback.
• Designing defensible workflows.
• Staying inspection-ready.
• Running global rollouts

Agents help teams move faster.

They do not decide what is safe, defensible, or durable

In MedTech, software is not just built.

It is designed, governed, operated, and defended

And gravity still applies.

There is something I keep coming back to in these conversations.

You can go from idea to prototype incredibly fast right now. That is the day-zero problem, and AI has essentially solved it. You can spit out working code, scaffold an integration, and stand up a proof of concept in a week

But the nuance around an actual business workflow — the day one and beyond activities — those are dramatically harder than day zero ever was

Software engineering done well is craftsmanship.

There is more to it than generating code and turning a prototype into something a regulated enterprise can depend on. It means thinking about edge cases, failure modes, upgrade paths, observability, and long-term operability. It means deleting as much as adding. Simplifying interfaces. Collapsing concepts down to what actually matters

Inside my own teams, I see impressive first versions all the time.

That is not the hard part anymore.

The hard part is everything that comes after

We-Should-Just-Build-This-Ourse…

‍

Faster Engineering Just Pushes Work Somewhere Else

There is a tradeoff that rarely makes it into the first ROI spreadsheet.

AI compresses build cycles. In regulated companies, that speed shows up downstream. More releases mean more validation, more SOP updates, more training, more compliance review, and more audit prep

Engineering gets cheaper.

Governance becomes the constraint

There is also a subtler version of this problem.

Agents make it easy to generate output at scale. More workflows. More automation. More code.

But in regulated environments, every new service or automation path increases surface area. More things to secure. More things to validate. More things to explain to auditors

Speed without discipline creates complexity faster.

For CTOs, that is an architectural concern.

For Regulatory leaders, that is an inspection risk.

Are You Trying to Be a Software Company?

This is the part of these conversations that most often gets skipped.

A MedTech company is not a software shop. Most are largely outsourced IT organizations, and there is nothing wrong with that. The core business is devices, science, R&D, manufacturing quality, clinical programs, and global commercialization

When internal teams talk about building major regulatory platforms, the question is not whether they can spin up a prototype.

It is whether they want to operate a full-time software company inside their enterprise

Building software at scale is a people problem. It is not a technology problem. The constraint is coordination, judgment, institutional knowledge, and sustained focus over years

The people problem does not get fixed by agents and AI.

Regulatory platforms are deeply vertical. They encode jurisdiction-specific rules, regulator expectations, submission templates, QMS integrations, inspection trails, and post-market obligations

That knowledge is earned slowly.

It lives in product decisions, data models, operating procedures, and support playbooks.

AI will reshape how these platforms evolve.

It does not remove the learning curve that created them

In some MedTech IT planning meetings, a new kind of confidence has started to show up.

Not everywhere. Not in every organization. But often enough that it is worth paying attention to.

It is subtle. Casual. The kind that appears when something new begins to feel inevitable

A VP of IT or a CIO sits in a planning meeting. Someone pulls up a demo. An AI agent drafts a regulatory summary, generates a workflow, and scaffolds an integration. It looks impressive. It is impressive

Then someone says it:

Why are we paying for a platform when we could build this ourselves?

I understand the impulse.

SaaS valuations are volatile. Boards are pressing on efficiency. Hiring is under scrutiny everywhere. AI arrives, and suddenly there is a clean story. Automate friction. Avoid headcount growth. Modernize everything

Some of that is real.

I am optimistic about AI. In the right hands, it is a genuine superpower

But hope, cost pressure, aggressive marketing, and very human psychology are colliding right now. That collision is shaping how executives talk about technology strategy

In regulated industries, that matters.

The Confirmation Bias Problem

When leaders already feel pressure to reduce costs or flatten organizations, they naturally gravitate toward stories that validate those instincts. Flashy demos and headlines about agents replacing departments reinforce the belief that a breakthrough must be right around the corner

Once that belief sets in, messy operational details get discounted. Risk gets deferred.

That does not make the technology fake.

It does explain why ambition so often outruns delivery reality

For CTOs and Regulatory leaders, this is the moment to slow the conversation down.

Because prototypes are not platforms.

What AI Actually Changes

Years ago, Harvard Business Review wrote about the “hidden data factory,” the idea that organizations accumulate thousands of small one-off efforts to clean data, reconcile systems, patch workflows, and keep operations moving. No single fix ever justifies a major initiative. In aggregate, it quietly costs millions

That concept maps directly to what AI is good at today.

Inside engineering organizations, we call this work toil.

The repetitive, manual, low-judgment effort that keeps systems running but should not consume the time of highly trained people. Environment setup. Data reconciliation. Migration scripts. Test generation. Documentation drafts. Classification lookups. Compliance artifacts

AI is excellent at eliminating toil. It removes friction, collapses queues, and gives teams back time

In regulated environments, that is meaningful.

But here is the distinction that matters:

‍

Eliminating toil does not eliminate accountability

It does not remove the need for architecture, UX design, validation strategy, regulatory interpretation, or operational ownership.

What it does is allow smaller, more senior teams to focus on the work that actually differentiates platforms.

That is very different than from saying agents replace the platforms themselves

And Why That Creates Bigger Problems Over Time

As EUDAMED implementation accelerates and the UDI/Devices module becomes mandatory in May of 2026, many MedTech companies have made a seemingly practical decision. They hand EUDAMED compliance to IT.

At first glance, the logic feels sound. EUDAMED is a system. It requires integrations, data transmission, and technical connectivity. IT already owns those capabilities, so the project lands there.

But this handoff reveals a deeper misunderstanding of what EUDAMED actually represents. It is a tool that enables manufacturers to meet ongoing regulatory obligations that touch product data, submissions, post-market activities, and lifecycle management.  EUDAMED also enables manufacturers’ ACTOR partners like Notified Bodies, Authorized Representatives, Importers, and Distributors to meet their obligations under those EU regulations. Treating it as an isolated, one-time IT project creates risks to EU regulatory compliance that grow and spread across partners over time. MDR/IVDR regulatory compliance cannot be established and maintained with a one-time technical integration.

The first problem with delegating EUDAMED to IT is what it signals internally. It frames the regulation as a single event rather than a continuous program.

EUDAMED is not just about getting data into a database. It requires ongoing updates tied to regulatory changes, product modifications, vigilance activities, certificates, and market status. Every change across the product lifecycle can trigger downstream updates in EUDAMED.

When EUDAMED is positioned as a one-time event, organizations underestimate the scope, effort, and ownership required to maintain compliance over time. That gap does not show up immediately. It appears months later when updates are missed; data falls out of sync, or responsibilities become unclear.

IT teams often take on EUDAMED with the expectation that once the pipes are built, the work is largely done. In reality, the opposite happens.

As regulatory data changes, IT becomes the default escalation point for updates they do not own and cannot validate. They are asked to manage regulatory timelines, interpret data requirements, and support continuous updates that fall outside their core mandate.

This creates friction on both sides. Regulatory teams feel blocked by technical dependencies. IT teams feel burdened by compliance work they were never meant to manage. Over time, updates slow down, workarounds emerge, and risk quietly increases.

The most damaging consequence of delegating EUDAMED to IT is architectural. When EUDAMED operates outside of a centralized Regulatory Information Management system, organizations lose the opportunity to reuse data and reduce burden across the business.

Most of the data required for EUDAMED already exists within product information management and resource planning systems. Product registrations, certificates, submissions, UDI, and post-market data are not new. They are part of the regulatory lifecycle. When EUDAMED is disconnected from RIM, teams are forced to duplicate work, reconcile inconsistencies, and manually manage updates across systems.

Instead of becoming a natural extension of regulatory operations, EUDAMED turns into another silo. One that increases workload rather than streamlining it.

Establishing and maintaining regulatory information in EUDAMED is a regulatory obligation, not a technical one. While IT plays a critical role in enablement and integration, there should be a strong partnership between regulatory and IT (or a third-party submitter), but IT shouldn’t own it completely.

When EUDAMED is managed as part of a centralized RIM approach, organizations gain consistency, traceability, and reuse. Regulatory teams can leverage existing data, control updates at the source, and reduce the ripple effects of change across departments. IT supports the infrastructure, but regulatory owns the process.

This shift also changes how organizations think about compliance. Instead of reacting to EUDAMED as a standalone requirement, they treat it as part of a broader regulatory operating model that supports long-term compliance and growth.

Delegating EUDAMED to IT is rarely a conscious strategy. It is usually a symptom of fragmented regulatory operations and unclear ownership.

As MedTech companies scale globally and regulatory expectations continue to evolve, these handoffs become harder to sustain. EUDAMED exposes the cost of treating regulatory compliance as a series of isolated projects rather than an ongoing operational discipline.

The companies that navigate EUDAMED successfully are not the ones with the most complex integrations. They are the ones that anchor EUDAMED within regulatory operations, supported by centralized RIM systems that establish data consistency and reduce duplication, improve visibility, and spread the burden across the organization in a controlled way.

Why Regulatory Operations Is Ready for Agentic AI

Regulatory operations teams are under increasing pressure. Global regulatory complexity is rising, data volumes continue to grow, and teams are expected to move faster, often without additional headcount. At the same time, employee turnover and fragmented systems make it harder to maintain continuity and institutional knowledge.

As outlined in the RIM & AI Maturity in MedTech Executive Guide, many organizations are still operating with scattered regulatory data, reactive processes, and manual workflows. These conditions increase compliance risk and slow growth.

This environment has created the conditions where a more advanced form of AI can deliver meaningful value. That is where agentic AI comes into play, not as a replacement for regulatory expertise, but as a way to strengthen how regulatory operations function day to day.

What Is Agentic AI and Why It Matters

Most AI used in regulatory environments today is assistive. It helps classify documents, extract text, or answer questions when prompted. Agentic AI goes further by operating within defined workflows and processes.

Agentic AI systems can monitor structured regulatory data continuously, identify upcoming risks or deadlines, recommend actions based on rules and historical context, and surface next steps within governed processes. Instead of responding to requests, agentic AI supports execution by working alongside regulatory teams inside their operational systems.

The distinction is important. In regulated environments, value does not come from generative output alone. It comes from intelligence that is embedded, auditable, and aligned with how regulatory work actually gets done.

Moving Regulatory Teams Off the Data Treadmill

The executive guide describes early-stage regulatory teams as being stuck on a back-office data treadmill. Highly skilled professionals spend a disproportionate amount of time searching for information, reconciling spreadsheets, and repeating manual tasks rather than applying their expertise strategically.

Agentic AI helps reduce this burden by continuously organizing and validating regulatory data, identifying missing metadata or inconsistencies early, and reducing reliance on individual memory or tribal knowledge. Over time, this improves not just efficiency, but operational resilience. Teams become less vulnerable to audits, turnover, and last-minute regulatory surprises.

Why Agentic AI Depends on Operational Maturity

One of the most important insights from the paper is that AI value scales with RIM maturity. Advanced AI capabilities are not effective without centralized regulatory information and standardized processes .

At higher maturity levels, AI can surface upcoming risks across markets and renewals, analyze submission history to recommend reusable content, and identify bottlenecks before they impact timelines. At this stage, agentic AI begins to function as an operational partner, helping teams anticipate issues rather than react to them.

This is also where many organizations encounter friction. Skipping foundational steps may create the appearance of progress, but it limits reliability and long-term impact. Agentic AI is only as effective as the data, governance, and workflows it operates within.

From Task Automation to Predictive Compliance

At the most mature stage of regulatory operations, AI becomes fully embedded in daily work. The guide describes this level as one where real-time monitoring, predictive analytics, and continuous improvement are standard practice .

In this environment, agentic AI supports predictive compliance by identifying emerging risks, highlighting resource constraints, and improving visibility across submissions and renewals. These insights allow teams to act earlier and with greater confidence.

The paper is clear on one point. AI enhances regulatory expertise, but it does not replace it. Human judgment remains essential for interpretation, decision-making, and accountability. The real value of agentic AI is that it frees regulatory professionals from low-value work so they can focus on the decisions that matter most .

Regulatory Operations as the Heart of Compliant Growth

The most significant impact of agentic AI is not automation alone. It is the elevation of regulatory operations from a reactive support function to the heart of compliant growth.

Organizations that invest in strong RIM foundations, data governance, and workflow integration are better positioned to apply AI in a way that is safe, scalable, and durable. When implemented thoughtfully, agentic AI helps regulatory operations keep pace with growth, reduce risk, and support faster, more confident decision-making across the business.

MedTech regulatory affairs teams are facing a turning point. Regulations are expanding in number and complexity, resources are limited, and manual processes cannot keep up. At the same time, artificial intelligence (AI) has become a serious topic of discussion in regulatory circles. Leaders are beginning to ask: How can AI help us manage change, reduce risk, and accelerate compliance efforts?

The answer is clear: AI is no longer just a buzzword. When combined with effective regulatory information management (RIM), it can be a powerful enabler of efficiency, accuracy, and strategic decision-making.

‍

Why AI is Trending in Regulatory Affairs

The Surge of Regulatory Data

Regulatory teams must now track requirements from multiple global markets. Each regulator frequently updates its regulations, guidances, templates, and recognized standards, which creates large volumes of data to organize and analyze. AI can scan and classify this information, highlight changes, and prepare it for structured use within RIM systems.

Doing More with Limited Resources

Most teams are expected to deliver more without additional staff. High turnover makes continuity difficult, and according to the 2024 RAPS Global Workforce Report, the number of professionals “open to work” has grown in North America and Europe. AI offers relief by taking on repetitive tasks such as document formatting or data entry, allowing experts to focus on higher-value work.

Global Complexity and Diverging Standards

No two markets are exactly alike. AI can help by flagging differences, surfacing potential risks, and recommending reusable content drawn from a company’s submission history. Faster, more accurate submissions directly improve time-to-market and compliance outcomes.

‍

The RIM & AI Adoption Maturity Model

Not every organization is ready to fully embrace AI. Success depends on RIM maturity: how structured and centralized your regulatory processes and data are. The RIM & AI Adoption Maturity Model provides a roadmap from basic to optimized states.

• Levels 0–2: Early Stage‍
  
  • Data is siloed and processes are ad hoc. AI provides value in isolated ways, such as cleansing records or scanning for regulatory changes.

• Level 3: Proactive
  
  • A RIM system centralizes information. AI begins to surface reminders, deadlines, and global impact assessments.

• Level 4: Well Managed‍
  
  • Processes are standardized across the lifecycle. AI generates insights, monitors KPIs, and supports reuse of regulatory content.

• Level 5: Optimized‍
  
  • AI is fully embedded, delivering predictive analytics, continuous monitoring, and smarter decision-making.

‍

Practical Applications of AI Today

Today, regulatory teams see the greatest opportunities in:

• Regulatory submissions: Automatically detecting changes in templates and suggesting updates.

• Document classification: Using natural language processing to tag and organize regulatory documents.

• Regulatory intelligence: Monitoring health authority updates and highlighting what matters most.

• Impact assessments: Linking changes (e.g., regulations/standards/design) directly to the affected products and registrations and evaluate the potential impact.

• Content reuse: Recommending approved content to accelerate submissions.

‍

How to Start Your AI Journey in Regulatory Affairs

Adopting AI is not about jumping to the most advanced capabilities overnight. Instead, consider these steps:

1. Assess your RIM maturity. Where does your organization sit on the 0–5 scale? What foundational gaps (data centralization, process standardization) need to be addressed first?

2. Identify quick wins. Focus on repetitive, rules-based tasks where AI can add value without major disruption.

3. Implement governance. Establish policies for safe, compliant AI use, particularly around data privacy and model training.

4. Pilot in phases. Start small, validate results, and expand AI use as confidence and maturity grow.

5. Keep people at the center. AI should enhance the expertise of regulatory professionals, not replace it.

‍

Building a Smarter Future for MedTech Compliance

AI is becoming a trending topic in regulatory affairs not just because it’s new, but because it directly addresses the challenges teams face: rising complexity, limited resources, and scattered data.

For organizations that take this approach, the benefits are clear: lower compliance risk, faster execution, and stronger competitive positioning. AI does not replace regulatory professionals. Instead, it enables them to spend less time on manual tasks and more time on strategic contributions that improve patient access to life-changing technologies.

In other words, AI isn’t about futuristic transformation. It’s about helping regulatory teams step off the “data treadmill” and reclaim their time for what matters most: bringing safe, life-changing medical technologies to patients faster.